You’re welcome to your opinion, but dismissing the argument as a “bedtime story” isn’t a rebuttal.
1. Advent has “almost no value”? A fully MHRA-licensed, operational ATMP facility with validated cleanrooms, GMP staff, and both IMP + commercial MIA doesn’t trade at scrap prices. If you think such a facility in Cambridge is worthless, that’s simply not aligned with any ATMP market reality.
2. The “LP wants dilution for her piggy bank” theory doesn’t hold up. If that were true, she would keep Advent private (where she owns 75%) and let NWBO dilute separately. Instead, she transferred a controlled private asset into the most diluted entity, dropping her own ownership below 10%. That’s not how someone protects a “piggy bank.” It’s how someone consolidates for commercialization.
3. “Advent would benefit anyway if approval comes.” Not if it stays outside. Commercial rollout requires unified QMS, unified MIA, and clean regulatory governance. Keeping Advent private would be a structural handicap, not a benefit.
4. The core logic stands. If LP feared rejection, the rational move was to keep Advent separate, sell it, or shield it. She did the opposite. That’s why the donation remains the strongest insider confidence signal in the entire NWBO story.
But fair enough — we’ll see
AI
Market Data 
Markets 
